Founded in 2019 by Dr. Rohan Dharmakumar, Cardio-Theranostics LLC is a development and commercialization company focusing on diagnosis, prevention and treatment of patients to suppress the incidence and progression of chronic heart disease and heart failure. While patient outcome is always the first priority, the Company excels at translating research discoveries into products that also meet physician and hospital needs while providing pharmaceutical partners with pipelines of commercially viable products.
Podcast: by Rohan Dharmakumar, Executive Director of the Krannert Cardiovascular Research Center and Founder of Cardio-Theranostics. IU Medicine Magazine. Brief introduction to Dr. Dharmakumar and his research https://medicine.iu.edu/magazine/steady-beats
Dr. Dharmakumar earned his Bachelor of Science in Physiology and Physics, his Master of Science in Mathematics and his PhD in Medical Biophysics from the University of Toronto. He received postdoctoral training in cardiovascular MRI at the University of Toronto and then Northwestern University. In 2006, he joined the faculty in the Department of Radiology at Northwestern. Subsequently he was recruited to Cedars-Sinai Medical Center in 2011 as associate professor. There he held various leadership roles at the Biomedical Imaging Research Institute, including associate director, director of translational cardiac imaging research and finally co-director of PET/MRI research. He was promoted to professor at the Cedars-Sinai in 2018, and UCLA in 2020. In 2021, Dr. Dharmakumar was recruited as the inaugural executive director of the Krannert Cardiovascular Research Center at the Cardiovascular Institute in Indiana University Schools of Medicine. In his leadership, Krannert Cardiovascular Research Center aspires to create a research base that embraces all aspects of science, engineering and medicine to transform our current understanding of cardiovascular disease for developing novel diagnostics and therapeutics to advance the care for patients most affected by heart disease.
Our mission is to remove cardiovascular disease from its current position as the leading cause of death in the United States and abroad. We are well on our way to doing so.
Our vision is that fundamental research focusing on cause-effect relationships enable us to develop more effective diagnostics and to discover divers of disease progression. Any other approach is purely speculative. The discovered relationships then drive products to prevent heart attacks and reduce heart damage (acute and chronic heart failure) following a heart attack.